Blood and tissue nitric oxide and malondialdehyde are prognostic indicators of localized prostate cancer

International Urology and Nephrology

Volumn 44, Issue 6, 2012, Pages 1691-1696

  Dillioglugil, Meltem Ozlen ^a   Mekık, Haluk ^b   Muezzinoglu, Bahar ^a   Ozkan, T Alp ^c   Demir, Cennet Gural ^a   Dillioglugil, Ozdal ^a  

^a KOCAELI UNIVERSITY   (Turkey)

^b Laboratory of Buyuk Istanbul Corlu   (Turkey)

^c Derince Training and Research Hospital ^*  (Turkey)

Author keywords

Malondialdehyde; Nitric oxide; Prostate cancer; PSA

Indexed keywords

MALONALDEHYDE; NITRIC OXIDE;

AGED; ARTICLE; BLOOD; CHEMISTRY; HUMAN; MALE; MIDDLE AGED; PROGNOSIS; PROSTATE TUMOR;

AGED; HUMANS; MALE; MALONDIALDEHYDE; MIDDLE AGED; NITRIC OXIDE; PROGNOSIS; PROSTATIC NEOPLASMS;

EID: 84877614447     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-012-0221-1     Document Type: Article

References (24)

1. Ames BN (1989) Endogenous oxidative DNA damage, aging, and cancer. Free Radic Res Commun 7(3-6):121-128
2. McCall MR, Frei B (1999) Can antioxidant vitamins materially reduce oxidative damage in humans? Free Radic Biol Med 26(7-8):1034-1053
3. Nanni S, Benvenuti V, Grasselli A, et al. (2009) Endothelial NOS, estrogen receptor beta, and HIFs cooperate in the activation of a prognostic transcriptional pattern in aggressive human prostate cancer. J Clin Invest 119(5):1093-1098
4. Yossepowitch O, Pinchuk I, Gur U, et al. (2007) Advanced but not localized prostate cancer is associated with increased oxidative stress. J Urol 178(4 Pt 1):1238-1243
5. Baltaci S, Orhan D, Gögüs C, et al. (2001) Inducible nitric oxide synthase expression in benign prostatic hyperplasia, low- and high-grade prostatic intraepithelial neoplasia and prostatic carcinoma. BJU Int 88(1):100-103
6. Reschner A, Harlin H, Laven B, et al. (2009) Expression of immunomodulating genes in prostate cancer and benign prostatic tissue. Anal Quant Cytol Histol 31(2):74-82
7. Lim HW, Hong S, Jin W, et al. (2005) Up-regulation of defense enzymes is responsible for low reactive oxygen species in malignant prostate cancer cells. Exp Mol Med 37(5):497-506
8. Almushatat AS, Talwar D, McArdle PA, et al. (2006) Vitamin antioxidants, lipid peroxidation and the systemic inflammatory response in patients with prostate cancer. Int J Cancer 118(4):1051-1053
9. Cortas NK, Wakid NW (1990) Determination of inorganic nitrate in serum and urine by a kinetic cadmium-reduction method. Clin Chem 36(8 Pt 1):1440-1443
10. Yoshioka T, Kawada K, Shimada T, et al. (1979) Lipid peroxidation in maternal and cord blood and protective mechanism against activated-oxygen toxicity in the blood. Am J Obstet Gynecol 135(3):372-376
11. Buege JA, Aust SD (1978) Microsomal lipid peroxidation. Methods Enzymol 52:302-310
12. Lowry OH, Rosebrough NJ, Farr AL, et al. (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193(1):265-275
13. Miyake H, Hara I, Kamidono S, et al. (2004) Oxidative DNA damage in patients with prostate cancer and its response to treatment. J Urol 171(4):1533-1536
14. Halliwell B, Whiteman M (2004) Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean? Br J Pharmacol 142(2):231-255
15. Tribble DL, Aw TY, Jones DP, et al. (1987) The pathophysiological significance of lipid peroxidation in oxidative cell injury. Hepatology 7(2):377-386
16. Kanko M, Ozden M, Maral H, et al. (2006) Effect of clopidogrel on nitric oxide levels in an ischemia reperfusion model. J Cardiovasc Pharmacol 48(1):797-801
17. Moncada S, Higgs A (1993) The l-arginine-nitric oxide pathway. N Engl J Med 329(27):2002-2012
18. Akyol O, Herken H, Uz E, et al. (2002) The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalance. Prog Neuropsychopharmacol Biol Psychiatry 26(5):995-1005
19. Fukumura D, Kashiwagi S, Jain RK (2006) The role of nitric oxide in tumour progression. Nat Rev Cancer 6(7):521-534
20. Wink DA, Vodovotz Y, Laval J, et al. (1998) The multifaceted roles of nitric oxide in cancer. Carcinogenesis 19(5):711-721
21. Klotz T, Bloch W, Volberg C, et al. (1998) Selective expression of inducible nitric oxide synthase in human prostate carcinoma. Cancer 82(10):1897-1903
22. Gradini R, Realacci M, Ginepri A, et al. (1999) Nitric oxide synthases in normal and benign hyperplastic human prostate: immunohistochemistry and molecular biology. J Pathol 189(2):224-229
23. Aaltomaa SH, Lipponen PK, Viitanen J, et al. (2000) The prognostic value of inducible nitric oxide synthase in local prostate cancer. BJU Int 86(3):234-239
24. Catalona WJ, Partin AW, Slawin KM, et al. (1998) Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter trial. JAMA 279(19):1542-1547